Related references
Note: Only part of the references are listed.The Relative Bioavailability and Effects of Food and Acid-Reducing Agents on Filgotinib Tablets in Healthy Subjects
Kacey Anderson et al.
CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT (2019)
Influence of age and renal impairment on the steady state pharmacokinetics of filgotinib, a selective JAK1 inhibitor
Florence Namour et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2018)
Filgotinib (GLPG0634/GS-6034), an oral selective JAK1 inhibitor, is effective as monotherapy in patients with active rheumatoid arthritis: results from a randomised, dose-finding study (DARWIN 2)
A. Kavanaugh et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Filgotinib (GLPG0634/GS-6034), an oral JAK1 selective inhibitor, is effective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis and insufficient response to MTX: results from a randomised, dose-finding study (DARWIN 1)
R. Westhovens et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Clinical remission in patients with moderate-to-severe Crohn's disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial
Severine Vermeire et al.
LANCET (2017)
Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Filgotinib, a Selective JAK-1 Inhibitor, After Short-Term Treatment of Rheumatoid Arthritis: Results of Two Randomized Phase IIa Trials
Frederic Vanhoutte et al.
ARTHRITIS & RHEUMATOLOGY (2017)
The JAK-STAT Pathway: Impact on Human Disease and Therapeutic Intervention
John J. O'Shea et al.
ANNUAL REVIEW OF MEDICINE, VOL 66 (2015)
Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Modeling of Filgotinib (GLPG0634), a Selective JAK1 Inhibitor, in Support of Phase IIB Dose Selection
Florence Namour et al.
CLINICAL PHARMACOKINETICS (2015)
Preclinical Characterization of GLPG0634, a Selective Inhibitor of JAK1, for the Treatment of Inflammatory Diseases
Luc Van Rompaey et al.
JOURNAL OF IMMUNOLOGY (2013)
MECHANISMS OF DISEASE JAKs and STATs in Immunity, Immunodeficiency, and Cancer
John J. O'Shea et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Jak1 Has a Dominant Role over Jak3 in Signal Transduction through γc-Containing Cytokine Receptors
Claude Haan et al.
CHEMISTRY & BIOLOGY (2011)
JAKs in pathology: Role of Janus kinases in hematopoietic malignancies and immunodeficiencies
William Vainchenker et al.
SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY (2008)
Structure, function and regulation of carboxylesterases
Tetsuo Satoh et al.
CHEMICO-BIOLOGICAL INTERACTIONS (2006)
A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease
H Ito et al.
GASTROENTEROLOGY (2004)
Share Paper
